Abstract
The Committee on Safety of Medicines (CSM) and National Institute for Health and Clinical Excellence have issued guidance on antidepressant use in depression in young people. An anonymous survey was sent to 692 UK consultants in child and adolescent psychiatry; the response rate was 70.1%. Almost all (95.1%) respondents said fluoxetine was their antidepressant of first choice (29.9% only prescribed fluoxetine), although use of sertraline and citalopram was common. The CSM advice had resulted in 68.4% switching to fluoxetine only, or mostly. Clinicians appear to be adhering national guidance. Guidance needs to be regularly updated to reflect current evidence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
